Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | HTT | P42858 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | XBP1 | P17861 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920563 | 0.80 | MAPT (0.56) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL13556583 | 0.79 | KMT2A (0.64) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL13853016 | 0.79 | HTT (0.58) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL13852827 | 0.79 | MEN1 (0.62) | MAPTRAB9AHTTSMN1; SMN2MEN1 | |
| SCHEMBL4916645 | 0.78 | MAPT (0.71) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL13852819 | 0.77 | NPC1 (0.62) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL18702740 | 0.76 | NR1H4 (0.56) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL13756246 | 0.76 | MAPT (0.81) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL2730172 | 0.76 | MAPT (0.81) | MAPTRAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL177853 | 0.75 | RAB9A (0.69) | MAPTRAB9AHTTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPT 1454/4885RAB9A 3041/4885HTT 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.